Walleye Capital’s Allogene Therapeutics ALLO Stock Holding History

Walleye Capital’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,400	Closed	-$69K	–	1695
2019 Q1	$69K	Buy	+2,400	New	+$69.6K	0.01%	1134

Other funds holding ALLO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Walleye Capital's ALLO Position: Q1 2024 in Review

Walleye Capital sold out of Allogene Therapeutics (ALLO) in Q1 2024, closing a stake of 69,411 shares — an estimated $223K sold.

Walleye Capital first reported a position in ALLO in Q2 2020 and held it in 4 quarters. The position peaked at $708K in Q2 2020. 161 funds tracked by Wall St. Rank hold ALLO as of Q1 2024.

Walleye Capital reported no remaining Allogene Therapeutics position as of Q1 2024 after selling out during the quarter.
Walleye Capital sold 69,411 Allogene Therapeutics shares in Q1 2024, an estimated $223K.
Walleye Capital first reported a position in Allogene Therapeutics in Q2 2020 and held it in 4 quarters.
Walleye Capital's Allogene Therapeutics position peaked at $708K in Q2 2020.
161 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2024.

Based on Walleye Capital's 13F filing for Q1 2024, filed 15 May 2024.